Similarly, in the AMI subgroup analysis of the primary CHD + T2DM cohort, the effect of short-term SGLT2 inhibitor use did not reach statistical significance (P > 0.05; Supplementary Table S22), which is likely attributable to the substantially reduced sample size in this particular subgroup analysis that critically constrained the statistical power. Here, SLC5A2 is linked to type 2 diabetes mellitus.